
News|Articles|February 1, 2004
Extended-release formulation of oxymorphone effective for pain relief in osteoarthritis
The opioid oxymorphone (Numorphan, Endo) delivered in a new extended-release (ER) formulation significantly improves standard measures of pain and physical function in osteoarthritis (OA) patients, researchers reported at the American College of Rheumatology 67th Annual Scientific Meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
500,000 Medicaid beneficiaries with diabetes to lose coverage by 2034
2
Ashley Holzworth-Nash, Pharm.D., Evernorth
3
Medicaid work requirements and how states may apply them: An in-depth discussion with Eric Levine, M.P.H., of Avalere Health
4
FDA approves first mRNA-based flu vaccine
5




















